methionine has been researched along with su 11248 in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Bellmunt, J; Choueiri, TK; Katz, L | 1 |
1 review(s) available for methionine and su 11248
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
1 other study(ies) available for methionine and su 11248
| Article | Year |
|---|---|
¹¹C-methionine positron-emission tomography and computed tomography (PET-CT) in evaluating metastatic transitional cell carcinoma response to sunitinib therapy.
Topics: Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Bone Neoplasms; Carbon Radioisotopes; Carcinoma, Transitional Cell; Humans; Indoles; Methionine; Positron-Emission Tomography; Pyrroles; Sunitinib; Tomography, X-Ray Computed; Treatment Outcome | 2010 |